Latest Medications News
TUESDAY, April 3 (HealthDay News) -- The Neupro (rotigotine) transdermal system has been approved by the U.S. Food and Drug Administration to treat advanced Parkinson's disease and moderate-to-severe restless leg syndrome, the Belgian drug maker UCB said Tuesday in a news release.
The continuous drug delivery patch was first approved by the FDA in 2007 to treat early-stage Parkinson's.
The dopamine agonist skin patch is believed to work by stimulating dopamine receptors within the caudate-putamen, the portion of the brain that regulates movement, the company said.
-- Scott Roberts
Copyright © 2012 HealthDay. All rights reserved.